Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2265-2274

  Cai, Shi Ying ^a   He, Hongwei ^a   Nguyen, Trong ^a   Mennone, Albert ^a   Boyer, James L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acid; Cholesterol; Hyperlipidemia; Nuclear receptor

Indexed keywords

CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; MESSENGER RNA; RETINOIC ACID; RETINOID X RECEPTOR; SMALL INTERFERING RNA; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; PPARGC1A PROTEIN, MOUSE; PREGNA-4,17-DIENE-3,16-DIONE; PREGNANE DERIVATIVE; RETINOID X RECEPTOR ALPHA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEPG2 CELL LINE; METABOLISM; MOUSE; MUTATION;

ANIMALS; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7-ALPHA-HYDROXYLASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; HEP G2 CELLS; HEPATOCYTES; HUMANS; MICE; MUTATION; PREGNENEDIONES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOID X RECEPTOR ALPHA; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSFECTION; TRETINOIN; TRANSCRIPTION FACTORS;

EID: 77956805082     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M005546     Document Type: Article

References (53)

1. Chiang, J. Y. 2004. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551.
2. Pullinger, C. R., C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. Verhagen, C. R. Rivera, S. J. Mulvihill, M. J. Malloy, et al. 2002. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110: 109-117.
3. Erickson, S. K., S. R. Lear, S. Deane, S. Dubrac, S. L. Huling, L. Nguyen, J. S. Bollineni, S. Shefer, H. Hyogo, D. E. Cohen, et al. 2003. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009.
4. Schwarz, M., E. G. Lund, K. D. Setchell, H. J. Kayden, J. E. Zerwekh, I. Bjorkhem, J. Herz, and D. W. Russell. 1996. Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271: 18024-18031.
5. Schaap, F. G., N. A. van der Gaag, D. J. Gouma, and P. L. Jansen. 2009. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 49: 1228-1235.
6. Chiang, J. Y. 2009. Bile acids: regulation of synthesis. J.Lipid Res. 50: 1959-1966.
7. Shin, D. J., J. A. Campos, G. Gil, and T. F. Osborne. 2003. PGC- 1alpha activates CYP7A1 and bile acid biosynthesis. J. Biol. Chem. 278: 50047-50052.
8. Bhalla, S., C. Ozalp, S. Fang, L. Xiang, and J. K. Kemper. 2004. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147.
9. Goodwin, B., S. A. Jones, R. R. Price, M. A. Watson, D. D. McKee, L. B. Moore, C. Galardi, J. G. Wilson, M. C. Lewis, M. E. Roth, et al. 2000. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell. 6: 517-526.
10. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, and D. J. Mangelsdorf. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 6: 507-515.
11. Stravitz, R. T., P. B. Hylemon, D. M. Heuman, L. R. Hagey, C. D. Schteingart, H. T. Ton-Nu, A. F. Hofmann, and Z. R. Vlahcevic. 1993. Transcriptional regulation of cholesterol 7 alpha-hydroxylase mRNA by conjugated bile acids in primary cultures of rat hepatocytes. J. Biol. Chem. 268: 13987-13993.
12. Chiang, J. Y., R. Kimmel, C. Weinberger, and D. Stroup. 2000. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275: 10918-10924.
13. Holt, J. A., G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. Donahee, Y. Wang, T. A. Mansfield, S. A. Kliewer, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17: 1581-1591.
14. Song, K. H., T. Li, E. Owsley, S. Strom, and J. Y. Chiang. 2009. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 49: 297-305.
15. Kim, I., S. H. Ahn, T. Inagaki, M. Choi, S. Ito, G. L. Guo, S. A. Kliewer, and F. J. Gonzalez. 2007. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48: 2664-2672.
16. Sinal, C. J., M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. Gonzalez. 2000. Targeted disruption of the nuclear receptor FXR/ BAR impairs bile acid and lipid homeostasis. Cell. 102: 731-744.
17. Wang, H., J. Chen, K. Hollister, L. C. Sowers, and B. M. Forman. 1999. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell. 3: 543-553.
18. Parks, D. J., S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. A. Kliewer, J. B. Stimmel, T. M. Willson, A. M. Zavacki, D. D. Moore, et al. 1999. Bile acids: natural ligands for an orphan nuclear receptor. Science. 284: 1365-1368. (Pubitemid 29289664)
19. Makishima, M., A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, M. V. Hull, K. D. Lustig, D. J. Mangelsdorf, and B. Shan. 1999. Identification of a nuclear receptor for bile acids. Science. 284: 1362-1365. (Pubitemid 29289663)
20. Chen, W., and J. Y. Chiang. 2003. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene. 313: 71-82.
21. Eloranta, J. J., D. Jung, and G. A. Kullak-Ublick. 2006. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol. Endocrinol. 20: 65-79.
22. Barbier, O., I. P. Torra, A. Sirvent, T. Claudel, C. Blanquart, D. Duran-Sandoval, F. Kuipers, V. Kosykh, J. C. Fruchart, and B. Staels. 2003. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology. 124: 1926-1940. (Pubitemid 36666787)
23. Denson, L. A., E. Sturm, W. Echevarria, T. L. Zimmerman, M. Makishima, D. J. Mangelsdorf, and S. J. Karpen. 2001. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology. 121: 140-147.
24. Ananthanarayanan, M., N. Balasubramanian, M. Makishima, D. J. Mangelsdorf, and F. J. Suchy. 2001. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276: 28857-28865.
25. Landrier, J. F., J. J. Eloranta, S. R. Vavricka, and G. A. Kullak-Ublick. 2006. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G476-G485.
26. Kast, H. R., C. M. Nguyen, C. J. Sinal, S. A. Jones, B. A. Laffitte, K. Reue, F. J. Gonzalez, T. M. Willson, and P. A. Edwards. 2001. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15: 1720-1728.
27. Claudel, T., Y. Inoue, O. Barbier, D. Duran-Sandoval, V. Kosykh, J. Fruchart, J. C. Fruchart, F. J. Gonzalez, and B. Staels. 2003. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 125: 544-555. (Pubitemid 36929436)
28. Stayrook, K. R., K. S. Bramlett, R. S. Savkur, J. Ficorilli, T. Cook, M. E. Christe, L. F. Michael, and T. P. Burris. 2005. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 146: 984-991.
29. Repa, J. J., S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289: 1524-1529.
30. Shulman, A. I., C. Larson, D. J. Mangelsdorf, and R. Ranganathan. 2004. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell. 116: 417-429.
31. Heyman, R. A., D. J. Mangelsdorf, J. A. Dyck, R. B. Stein, G. Eichele, R. M. Evans, and C. Thaller. 1992. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 68: 397-406.
32. Zavacki, A. M., J. M. Lehmann, W. Seol, T. M. Willson, S. A. Kliewer, and D. D. Moore. 1997. Activation of the orphan receptor RIP14 by retinoids. Proc. Natl. Acad. Sci. USA. 94: 7909-7914.
33. Cai, S. Y., L. Xiong, C. G. Wray, N. Ballatori, and J. L. Boyer. 2007. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1400-R1409.
34. Ellis, C. N., N. A. Swanson, R. C. Grekin, N. G. Goldstein, D. R. Bassett, T. F. Anderson, and J. J. Voorhees. 1982. Etretinate therapy causes increases in lipid levels in patients with psoriasis. Arch. Dermatol. 118: 559-562.
35. Bershad, S., A. Rubinstein, J. R. Paterniti, N. A. Le, S. C. Poliak, B. Heller, H. N. Ginsberg, R. Fleischmajer, and W. V. Brown. 1985. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N. Engl. J. Med. 313: 981-985.
36. O'Leary, T. J., I. E. Simo, N. Kanigsberg, J. Walker, J. C. Goodall, and T. C. Ooi. 1987. Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy. Clin. Invest. Med. 10: 355-360.
37. Fex, G. A., A. Aronsson, A. Andersson, K. Larsson, and P. Nilsson- Ehle. 1996. In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur. J. Clin. Chem. Clin. Biochem. 34: 3-7.
38. Zane, L. T., W. A. Leyden, A. L. Marqueling, and M. M. Manos. 2006. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch. Dermatol. 142: 1016-1022.
39. Brelsford, M., and T. C. Beute. 2008. Preventing and managing the side effects of isotretinoin. Semin. Cutan. Med. Surg. 27: 197-206.
40. Perez-Aguilar, F., M. Breto, B. Alegre, and J. Berenguer. 1985. Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution. Digestion. 31: 225-233. (Pubitemid 15059820)
41. Nahoum, V., E. Perez, P. Germain, F. Rodriguez-Barrios, F. Manzo, S. Kammerer, G. Lemaire, O. Hirsch, C. A. Royer, H. Gronemeyer, et al. 2007. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc. Natl. Acad. Sci. USA. 104: 17323-17328.
42. Cai, S. Y., S. Gautam, T. Nguyen, C. J. Soroka, C. Rahner, and J. L. Boyer. 2009. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology. 136: 1060-1069.
43. Yang, N., R. Schule, D. J. Mangelsdorf, and R. M. Evans. 1991. Characterization of DNA binding and retinoic acid binding properties of retinoic acid receptor. Proc. Natl. Acad. Sci. USA. 88: 3559-3563.
44. Lew, J. L., A. Zhao, J. Yu, L. Huang, N. De Pedro, F. Pelaez, S. D. Wright, and J. Cui. 2004. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. 279: 8856-8861.
45. Li, T., A. Jahan, and J. Y. Chiang. 2006. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/ c-jun pathway in human liver cells. Hepatology. 43: 1202-1210.
46. Urizar, N. L., A. B. Liverman, D. T. Dodds, F. V. Silva, P. Ordentlich, Y. Yan, F. J. Gonzalez, R. A. Heyman, D. J. Mangelsdorf, and D. D. Moore. 2002. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 296: 1703-1706.
47. Biagini, C. P., E. Boissel, F. Borde, V. E. Bender, M. Bouskila, F. Blazy, L. Nicaise, A. Mignot, D. Cassio, and S. Chevalier. 2006. Investigation of the hepatotoxicity profile of chemical entities using Liverbeads and WIF-B9 in vitro models. Toxicol. In Vitro. 20: 1051-1059.
48. Urbach, J., and R. R. Rando. 1994. Isomerization of all-trans-retinoic acid to 9-cis-retinoic acid. Biochem. J. 299: 459-465.
49. Shih, T. W., T. H. Lin, Y. F. Shealy, and D. L. Hill. 1997. Non-enzymatic isomerization of 9-cis-retinoic acid catalyzed by sulfhydryl compounds. Drug Metab. Dispos. 25: 27-32.
50. Marrapodi, M., and J. Y. Chiang. 2000. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41: 514-520.
51. Dussault, I., R. Beard, M. Lin, K. Hollister, J. Chen, J. H. Xiao, R. Chandraratna, and B. M. Forman. 2003. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278: 7027-7033.
52. Hoeke, M. O., J. R. Plass, J. Heegsma, M. Geuken, D. van Rijsbergen, J. F. Baller, F. Kuipers, H. Moshage, P. L. Jansen, and K. N. Faber. 2009. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters. Hepatology. 49: 151-159.
53. Kassam, A., B. Miao, P. R. Young, and R. Mukherjee. 2003. Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J. Biol. Chem. 278: 10028-10032.